Partner Dov Grossman has been recognized as an Emerging Therapies/Life Sciences Trailblazer by The National Law Journal for his representation of Pfizer in three inter partes review proceedings before the Patent Trial and Appeal Board (“PTAB”) challenging uniQure biopharma patents involving gene therapy for hemophilia B.  Dov and his team successfully persuaded the PTAB to institute the three trials over uniQure’s objection.  Then, in November 2022, following Dov’s oral argument, the PTAB ruled in Pfizer’s favor, issuing three final written decisions in which it invalidated all 26 claims of the challenged patents. 
 
Dov is a member of the firm’s Patent Litigation practice group, and for nearly 20 years he has been litigating patent matters on behalf of some of the world’s largest biopharmaceutical companies to protect their most important products.  An accomplished trial lawyer with a background in chemistry—including medicinal chemistry—Dov has served as lead counsel in a variety of biopharmaceutical disputes, both in federal district court and before the PTAB. 
 
Click here to read Dov’s full Trailblazer profile.